Clinical Trials Logo

Filter by:
NCT ID: NCT06232577 Recruiting - Clinical trials for Intra-abdominal Cancer

5x-Multiplier vs 3-Tier Model for Discharge Opioid Prescriptions After Intra-abdominal Cancer Surgery: A Randomized Clinical Trial

Start date: March 27, 2024
Phase: Phase 2
Study type: Interventional

To compare 2 different models for prescribing opioid pain medication to provide better pain control to participants with an abdominal cancer who are having surgery.

NCT ID: NCT06232551 Not yet recruiting - Clinical trials for Deep Vein Thrombosis

Alerting Providers at Patient Hospital Discharge to Consider Prescribing Rivaroxaban to Reduce Venous Thromboembolism

eVTE
Start date: March 1, 2024
Phase: N/A
Study type: Interventional

A new algorithm derived from only patient age and components of the complete blood count and basic metabolic panel can identify patients discharged from the hospital who may benefit from a blood thinner (called rivaroxaban) to decrease their risk of blood clots, and for whom the risk of bleeding is minimal. The purpose of this study is to evaluate the use of a pop-up alert, which will be seen by clinicians when a discharging patient has been identified as being someone for whom the risk of blood clots is high, but for whom bleeding risk is estimated to be low. The pop-up alert will be enabled in a sequential fashion for each group of hospitals in 1 month blocks. We will look to see if the pop-up alert changes the number of patients who receive rivaroxaban. We will also measure the outcomes of blood clots and bleeding among all discharging patients.

NCT ID: NCT06232512 Recruiting - Hypoesthesia Clinical Trials

Multimodal Haptic Feedback for Plantar Sensory Substitution

Start date: April 20, 2023
Phase: N/A
Study type: Interventional

The study will explore the use of a haptic device for sensory substitution in individuals with a movement disorder that has caused loss of plantar sensation. The haptic device consists of two components. The first element is a flexible insole with embedded pressure-sensing elements that transmit the spatial patterns of applied foot pressure over time. The second element is a haptic receiver with embedded actuators that vibrate or heat up in proportion to the transmitted pressure patterns, thus substituting the patient's lost plantar sensation.

NCT ID: NCT06232460 Not yet recruiting - Tolerance Clinical Trials

An Open Label, Dose-escalation Study, Assessing the Safety and Tolerability of a Collagen Peptide

Start date: January 29, 2024
Phase: N/A
Study type: Interventional

This study evaluates the safety and tolerability of three different doses (5 g, 10 g and 20 g) of a collagen powder in healthy adults over a 12-week period.

NCT ID: NCT06232447 Recruiting - Cigarette Smoking Clinical Trials

Menthol, Inflammation, and Nicotine Transition Study

MINT
Start date: March 26, 2024
Phase: N/A
Study type: Interventional

This study will focus on examining the potential impact of menthol flavoring in cigarettes on biomarkers of systemic inflammation as a subclinical indicator of cardiovascular disease risk.

NCT ID: NCT06232408 Recruiting - Clinical trials for Advanced Solid Tumor

LIONS (PLK4 Inhibitor in Advanced Solid Tumors)

Start date: February 14, 2024
Phase: Phase 1
Study type: Interventional

The primary objective of this study is to identify a safe and tolerated dose and schedule of the orally administered PLK4 inhibitor RP-1664. In addition, this study will examine the pharmacokinetics (PK), pharmacodynamics (PD) and preliminary anti-tumor activity of RP-1664 in advanced solid tumors.

NCT ID: NCT06232317 Enrolling by invitation - Surgery Clinical Trials

Feasibility and Acceptability of ReCognitionVR-based Cognitive Stimulation in Surgical Patients

Start date: December 9, 2023
Phase: N/A
Study type: Interventional

This study aims to assess the feasibility, acceptability, and safety of using ReCognitionVR virtual reality-based software in older surgical patients. Results from this study will be used to inform the design of a future study in critically ill hospitalized patients at risk for delirium.

NCT ID: NCT06231862 Completed - Sepsis Clinical Trials

Gene Expression Objective Definition of Early Sepsis In Children

GEODESIC
Start date: March 1, 2019
Phase:
Study type: Observational

GEODESIC is a prospective descriptive cohort investigation that will examine the generalizability of the novel host gene expression biomarkers, SeptiCyteTM LAB, SeptiCyteTM VIRUS, SeptiCyteTM BACT, and SeptiCyteTM TRIAGE (collectively 18 genes or SeptiCyteTM LVBT) and SeptiCyteTM RAPID, for differentiating children with bacterial sepsis, versus severe viral illness, versus non-infectious related systemic inflammatory response syndrome.

NCT ID: NCT06231810 Recruiting - Stroke Clinical Trials

Tracking a Tactile Signal Along the Nervous System

Start date: February 29, 2024
Phase: N/A
Study type: Interventional

Quantify the flow of a tactile signal from the stimulus at the finger at the peripheral nervous system (PNS), to the central nervous system (CNS), and to cognitive perception at the brain in young adults (Aim 1) and individuals with and without stroke (Aim 2).

NCT ID: NCT06231563 Not yet recruiting - Parkinson?s Disease Clinical Trials

Ketamine for Veterans With Parkinson's Disease

KPD
Start date: July 1, 2024
Phase: Phase 2
Study type: Interventional

Parkinson's disease (PD) is a devastating illness that has a growing impact on Veterans. One of the most disabling symptoms is depression, which is common in PD and linked to poor quality of life and higher risk of suicide. Unfortunately, there is a lack of effective treatments for depression in PD. Ketamine, which has rapid and potent antidepressant effects, is a potential option but has not been tested in Veterans with PD. Studies in rodents show that ketamine may not only improve depression in PD, it may target two of the underlying drivers of the disease: (1) reduced neuroplasticity, or the brain's ability to adapt and remodel itself; and (2) elevated inflammation. The investigators are conducting a randomized, placebo-controlled study to examine if a dose of intravenous (IV) ketamine improves depression in Veterans with PD. The investigators will also examine ketamine's effects on neuroplasticity and inflammation, which will help us understand how ketamine works in PD and if it can be a useful treatment for Veterans with the disease. This study will lay groundwork for a larger clinical trial across multiple VA sites.